Bank of Montreal Can Has $5.17 Million Position in Retrophin Inc (RTRX)

Bank of Montreal Can lifted its position in shares of Retrophin Inc (NASDAQ:RTRX) by 12.5% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 180,098 shares of the biopharmaceutical company’s stock after buying an additional 20,019 shares during the quarter. Bank of Montreal Can owned approximately 0.44% of Retrophin worth $5,174,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in RTRX. PNC Financial Services Group Inc. lifted its stake in shares of Retrophin by 1,404.9% during the 2nd quarter. PNC Financial Services Group Inc. now owns 272,328 shares of the biopharmaceutical company’s stock valued at $7,424,000 after buying an additional 254,232 shares in the last quarter. BlackRock Inc. lifted its stake in shares of Retrophin by 7.7% during the 2nd quarter. BlackRock Inc. now owns 3,512,643 shares of the biopharmaceutical company’s stock valued at $95,754,000 after buying an additional 249,833 shares in the last quarter. Russell Investments Group Ltd. lifted its stake in shares of Retrophin by 1,502.1% during the 2nd quarter. Russell Investments Group Ltd. now owns 199,377 shares of the biopharmaceutical company’s stock valued at $5,422,000 after buying an additional 186,932 shares in the last quarter. Macquarie Group Ltd. lifted its stake in shares of Retrophin by 12.3% during the 2nd quarter. Macquarie Group Ltd. now owns 1,617,618 shares of the biopharmaceutical company’s stock valued at $44,096,000 after buying an additional 177,604 shares in the last quarter. Finally, Handelsbanken Fonder AB purchased a new position in shares of Retrophin during the 2nd quarter valued at $4,498,000.

In other news, CEO Steve Aselage sold 12,000 shares of the business’s stock in a transaction dated Friday, August 31st. The shares were sold at an average price of $32.00, for a total value of $384,000.00. Following the sale, the chief executive officer now directly owns 257,883 shares in the company, valued at approximately $8,252,256. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 3.67% of the company’s stock.



Retrophin stock opened at $25.66 on Thursday. Retrophin Inc has a twelve month low of $20.09 and a twelve month high of $33.00. The stock has a market capitalization of $1.02 billion, a PE ratio of -17.11 and a beta of 1.08.

A number of analysts have issued reports on RTRX shares. BidaskClub upgraded shares of Retrophin from a “hold” rating to a “buy” rating in a report on Tuesday, August 28th. Zacks Investment Research upgraded shares of Retrophin from a “sell” rating to a “hold” rating in a report on Thursday, September 27th. Canaccord Genuity started coverage on shares of Retrophin in a report on Friday, August 17th. They issued a “buy” rating on the stock. Finally, Jefferies Financial Group started coverage on shares of Retrophin in a report on Tuesday. They issued a “buy” rating and a $44.00 price target on the stock. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $43.50.

About Retrophin

Retrophin, Inc, a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.

Featured Story: Treasury Bonds

Want to see what other hedge funds are holding RTRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Retrophin Inc (NASDAQ:RTRX).

Institutional Ownership by Quarter for Retrophin (NASDAQ:RTRX)

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply